Legal & General Group Plc Buys 1,339 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Legal & General Group Plc boosted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 57,753 shares of the medical instruments supplier’s stock after purchasing an additional 1,339 shares during the period. Legal & General Group Plc’s holdings in LeMaitre Vascular were worth $5,321,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of LMAT. New York State Teachers Retirement System boosted its position in shares of LeMaitre Vascular by 1.2% during the 4th quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier’s stock worth $755,000 after acquiring an additional 100 shares in the last quarter. Flputnam Investment Management Co. lifted its stake in LeMaitre Vascular by 3.6% during the fourth quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier’s stock worth $269,000 after purchasing an additional 102 shares during the last quarter. Norden Group LLC boosted its holdings in shares of LeMaitre Vascular by 4.5% in the 4th quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier’s stock valued at $218,000 after purchasing an additional 103 shares in the last quarter. Blue Barn Wealth LLC increased its stake in shares of LeMaitre Vascular by 4.4% in the 4th quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier’s stock valued at $229,000 after purchasing an additional 104 shares during the last quarter. Finally, Shaker Investments LLC OH raised its holdings in shares of LeMaitre Vascular by 0.8% during the 4th quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier’s stock worth $1,285,000 after buying an additional 112 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Lake Street Capital raised their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price objective for the company. Finally, Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $95.25.

LeMaitre Vascular Stock Up 1.9 %

Shares of NASDAQ:LMAT opened at $86.28 on Monday. The business has a fifty day simple moving average of $87.85 and a 200 day simple moving average of $93.52. LeMaitre Vascular, Inc. has a 12-month low of $62.40 and a 12-month high of $109.58. The firm has a market cap of $1.95 billion, a P/E ratio of 47.15, a P/E/G ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.49. The business had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. As a group, equities research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were issued a dividend of $0.20 per share. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 dividend on an annualized basis and a yield of 0.93%. The ex-dividend date was Thursday, March 13th. LeMaitre Vascular’s dividend payout ratio (DPR) is 41.24%.

Insider Buying and Selling

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the company’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares in the company, valued at $456,915.68. This represents a 26.53 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.79% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.